Generic Drug Alert: FDA Approves Generic Version of Lithobid

Quick generic drug approval bulletin for today. If you have a family member or other loved suffers from manic depression, the U.S. Food and Drug Administration has given Glenmark final approval for Lithium Carbonate extended release tablets, a generic version of Noven Pharmaceuticals’ prescription drug Lithobid which treats manic episodes of biopolar disorder. According to the National Institute of Mental Health, the possible consequences of untreated manic depression include shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.

Considering a thirty-day supply of brand-name Lithobid is currently running about $250, generic extended-release Lithium Carbonate could easily be a major savings for the families of many manic depressive, bipolar disorder patients, so if someone in your family suffers from manic depressive, bipolar disorder and is on Lithobid, you should ask their doctor if they are an appropriate candidate for the Lithobid generic counterpart.

Glenmark’sextended-release Lithium Carbonate tablets will be available in 300 mg strength and is indicated for the treatment of manic depression and bipolar disorder.

Does someone in your family use Lithobidl? Tell us about it!

Related posts:

1. FDA Approves Generic Version of Blood Pressure Drug Plendil (Felodipine)
2. FDA Approves Generic Version of Aricept for Alzheimer’s To Be Sold Immediately
3. Generic Drug Alert: FDA Approves Generic Version of Lovenox Blood-Thinner
4. New Generic Drug Approval: Generic Aricept for Alzheimer's
5. Generic Drug Alert: Patent on Strattera Ruled Invalid, Generic Versions Of Strattera to Hit the Market